Cellectis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!

About CLLS

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. 

CEO
André Choulika
CEOAndré Choulika
Employees
222
Employees222
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
2000
Founded2000
Employees
222
Employees222

CLLS Key Statistics

Market cap
353.38M
Market cap353.38M
Price-Earnings ratio
-14.04
Price-Earnings ratio-14.04
Dividend yield
Dividend yield
Average volume
118.46K
Average volume118.46K
High today
$5.05
High today$5.05
Low today
$4.62
Low today$4.62
Open price
$5.05
Open price$5.05
Volume
167.78K
Volume167.78K
52 Week high
$5.48
52 Week high$5.48
52 Week low
$1.10
52 Week low$1.10

Stock Snapshot

The current Cellectis(CLLS) stock price is $4.68, with a market capitalization of 353.38M. The stock trades at a price-to-earnings (P/E) ratio of -14.04.

During the trading session on 2025-12-13, Cellectis(CLLS) shares reached a daily high of $5.05 and a low of $4.62. At a current price of $4.68, the stock is +1.3% higher than the low and still -7.3% under the high.

Trading activity shows a volume of 167.78K, compared to an average daily volume of 118.46K.

The stock's 52-week range extends from a low of $1.10 to a high of $5.48.

The stock's 52-week range extends from a low of $1.10 to a high of $5.48.

CLLS News

TipRanks 6d
Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.